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Abstract
Background: Evidence shows significant heterogeneity in astrocyte gene expression and function. We previously
demonstrated that brain-derived neurotrophic factor (BDNF) exerts protective effects on whole brain primary
cultured rat astrocytes treated with 3-nitropropionic acid (3NP), a mitochondrial toxin widely used as an in vitro
model of Huntington’s disease (HD). Therefore, we now investigated 3NP and BDNF effects on astrocytes from two
areas involved in HD: the striatum and the entire cortex, and their involvement in neuron survival.
Methods: We prepared primary cultured rat cortical or striatal astrocytes and treated them with BDNF and/or 3NP
for 24 h. In these cells, we assessed expression of astrocyte markers, BDNF receptor, and glutamate transporters,
and cytokine release. We prepared astrocyte-conditioned medium (ACM) from cortical and striatal astrocytes and
tested its effect on a cellular model of HD.
Results: BDNF protected astrocytes from 3NP-induced death, increased expression of its own receptor, and
activation of ERK in both cortical and striatal astrocytes. However, BDNF modulated glutamate transporter
expression differently by increasing GLT1 and GLAST expression in cortical astrocytes but only GLT1 expression in
striatal astrocytes. Striatal astrocytes released higher amounts of tumor necrosis factor-α than cortical astrocytes in
response to 3NP but BDNF decreased this effect in both populations. 3NP decreased transforming growth factor-β
release only in cortical astrocytes, whereas BDNF treatment increased its release only in striatal astrocytes. Finally,
we evaluated ACM effect on a cellular model of HD: the rat striatal neuron cell line ST14A expressing mutant
human huntingtin (Q120) or in ST14A cells expressing normal human huntingtin (Q15). Neither striatal nor cortical
ACM modified the viability of Q15 cells. Only ACM from striatal astrocytes treated with BDNF and ACM from 3NP +
BDNF-treated striatal astrocytes protected Q120 cells, whereas ACM from cortical astrocytes did not.
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Conclusions: Data suggest that cortical and striatal astrocytes respond differently to mitochondrial toxin 3NP and
BDNF. Moreover, striatal astrocytes secrete soluble neuroprotective factors in response to BDNF that selectively
protect neurons expressing mutant huntingtin implicating that BDNF modulation of striatal astrocyte function has
therapeutic potential against neurodegeneration.
Keywords: BDNF, Striatal astrocytes, Cortical astrocytes, 3-Nitropropionic acid, Huntington’s disease, Glutamate
transporters, TNF-α, TGF-β, Astrocyte-conditioned medium, ST14A-Q120 striatal neurons
Background
Huntington’s disease (HD) is an autosomal inherited
neurodegenerative disorder in which the huntingtin gene
undergoes an expansion of CAG triplets that produces
the incorporation of polyglutamines to N-terminal re-
gion of the huntingtin protein (Htt). HD is characterized
by the selective death of medium spiny GABAergic neu-
rons in the striatum (basal ganglia) and, to a lesser ex-
tent, of cortical pyramidal neurons located mainly in
layer V of the prefrontal cortex producing a progressive
loss of motor and cognitive functions [1, 2]. Htt is
expressed throughout the body, although its levels are
higher in the central nervous system (CNS) [3]. Mutant
huntingtin (mHtt) is believed to be toxic to neurons be-
cause it acquires an abnormal conformation forming in-
clusions in cytoplasm, nucleus, and also in axonal
terminals as a consequence of failure in its degradation
[4]. Other mechanisms such as modulation of transcrip-
tion, proteasomal dysfunction, axonal transport, mito-
chondrial dysregulation, and excitotoxicity are also
involved in HD pathogenesis. Brain-derived neuro-
trophic factor (BDNF) is a neurotrophin that promotes
neuron survival and differentiation. BDNF was shown to
exert neuroprotection against excitotoxicity involved in
the degeneration of striatal neurons in HD [5]. Accumu-
lated findings showed that BDNF’s mRNA and protein
levels are significantly reduced in post-mortem samples
from human HD cortex and striatum [6, 7]. Although
this decrease is due to reduced BDNF transcription, it
could also be caused by a defect in its transport [7, 8].
Depletion of BDNF in the striatum is a key pathogenic
feature in HD, possibly responsible for the selective
neuron vulnerability in this disease [4].
BDNF induces its effects through two types of recep-
tors: it binds with high affinity to the tyrosine kinase re-
ceptor related to tropomyosin B (TrkB), and with low
affinity to the p75 neurotrophin receptor, to which all
neurotrophins could also be attached [9]. The binding of
BDNF to TrkB induces its dimerization and autophos-
phorylation in the intracellular kinase domain, followed
by activation of several intracellular signaling pathways.
Two isoforms of TrkB generated by alternative splicing
are abundantly expressed in the CNS: TrkB full length
(TrkB-FL) and TrkB truncated 1 isoform (TrkB-T1)
[10]. Through TrkB-FL, BDNF induces neuron differen-
tiation, proliferation, and survival in the CNS [11–13].
Truncated TrkB-T1 lacks the kinase domain but con-
tains a short isoform-specific cytoplasmic domain [14].
TrkB-T1 expression is the most abundant TrkB isoform
in the adult rodent brain [15]. TrkB-T1 can oppose
TrkB-FL function, BDNF binds TrkB-T1 instead of
TrkB-FL which internalizes BDNF but does not autop-
hosphorylate, thereby acting as a dominant negative re-
ceptor. However, TrkB-T1 has also been shown to
induce neurite outgrowth and to regulate changes in the
cytoskeleton [16]. Another study concluded that BDNF,
through TrkB-T1, can activate signaling pathways such
as extracellular signal-regulated kinase (ERK) and Akt,
inducing neural stem cell proliferation [17]. We also
demonstrated recently that TrkB-T1 is the major iso-
form expressed by astrocytes and that BDNF can induce
protection from serum deprivation and 3-nitropropionic
acid (3NP)-induced cell death through this receptor [18].
Activation of TrkB-T1 by BDNF was also proved re-
cently to induce cortical astrocyte morphogenesis [19].
Astrocytes, the most numerous cell type in the CNS,
have wide-ranging functions helping to maintain brain
homeostasis. These cells are also activated against tissue
damage or pathogens and are capable of producing a
wide variety of pro-inflammatory mediators such as cy-
tokines and chemokines. Neuroinflammation produced
by the sustained activation of astrocytes over time is
considered an important component in the development
of neurodegenerative diseases [20]. Astrocytes can also
play an important role in different stages of neurodegen-
eration that contribute to neuronal death. Marked astro-
gliosis was evidenced in HD patients and HD animal
models [1, 21, 22]. Astrocytes maintain physiological
levels of glutamate in the extracellular space. Accumula-
tion of glutamate in the synaptic space produces neuron
excitation; this accumulation was reported in several
neurodegenerative diseases such as HD [23]. Since glu-
tamate cannot be metabolized at the extracellular level,
it has to be removed from the synaptic space. Thus, as-
trocytes have specific glutamate transporters: excitatory
amino acid transporter 2 or, in the rat, glutamate trans-
porter 1 (GLT1) and excitatory amino acid transporter 1
or, in the rat, glutamate aspartate transporter 1 (GLAS
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T), both of these primarily responsible for glutamate up-
take in the brain [24]. Also, research is beginning to ad-
dress the heterogeneity of astrocytes. Evidence shows
significant heterogeneity in many aspects of astrocytes,
including morphology, gene expression profile, physio-
logical properties, and function [25]. However, few stud-
ies have examined the role of astrocytes from different
regions in HD. Very recently, a detailed study using
transcriptomics and proteomics investigated the differ-
ences between control striatal astrocytes and HD striatal
astrocytes, finding early dysfunction of astrocytes in two
murine models of HD [26]. However, no data exists yet
comparing different brain region astrocytes in HD.
Mitochondrial dysfunction is involved in the patho-
genesis of HD. Systemic injection of 3NP, an irreversible
inhibitor of mitochondrial complex II succinate de-
hydrogenase located in the inner membrane of the mito-
chondria, induces symptoms and mitochondrial
dysfunction similar to those in HD patients [27]. ST14A
cells are derived from embryonic rat striatal neurons
with features of medium-sized spiny neurons [28, 29].
ST14A/Q15 (Q15) cells express the N-terminal fragment
of human Htt with a 15 glutamine region (15 CAG re-
peats) and ST14A/Q120 (Q120) cells express the N-
terminal fragment of human mHtt with a 120 glutamine
region (120 CAG repeats). Q120 cells expressing mHtt
fragments are more susceptible to death by 3NP than
Q15 cells [30]. We have already proved that 3NP de-
creases viability in both cell lines in a dose-dependent
manner [31]. We have previously demonstrated that
BDNF decreases astrocyte death and oxidative stress in-
duced by 3NP through TrkB-T1 receptor [18]. Since the
most affected region in HD is the striatum, and then the
cortex, we explored differences between astrocytes from
these two areas. The aim of this study was to further in-
vestigate the mechanisms of BDNF protection and 3NP




TrkB inhibitor (ANA-12, N-[2-[[(Hexahydro-2-oxo-1H-
azepin-3-yl)amino]carbonyl]phenyl]-benzo[b]thiophene-
2-carboxamide Cat#SML0209) and 3-nitropropionic acid
(3NP, Cat#N22908) 3-[4,5-dimethylthiazol-2-yl]-2,5-di-
phenyltetrazolium bromide (MTT, Cat#M5655) were
obtained from Sigma-Aldrich Argentina. Ultrapure bac-
terial lipopolysaccharide (LPS) (Escherichia coli, 0111:B4,
Cat#tlrl-3pelps) was from Invivogen (USA); BDNF was
purchased from Alomone (Cat#B-250). Culture media
and supplements were acquired from Invitrogen
Argentina. All other media and supplements were ob-
tained from Sigma-Aldrich Argentina, unless otherwise
specified.
Animals
Wistar rats (RRID:RGD_13508588) were housed in a
temperature controlled facility at 25 °C on a 12 h light/
12 h dark cycle with access to lab chow and water ad
libitum. We bred these rats in our facility with one male
and two females per cage. All animal care and experi-
mental procedures were approved by the Institutional
Animal Care and Use Committee of the School of Medi-
cine of the University of Buenos Aires (EXP-
UBA0049923/2015), in line with the National Institutes
of Health Guidelines for the Care and Use of Laboratory
Animals.
Cell culture
Rat cerebral cortices or the striatum from 1- to 2-day-old
Wistar rat pups were dissected and astrocytes were pre-
pared as previously described [18]. Cells were seeded and
maintained in Dulbecco’s modified eagle medium
(DMEM)/F-12 medium containing 10% fetal bovine
serum, 50 μg/ml streptomycin-50 U penicillin in 75 cm2
poly-L-lysine coated (10 μg/ml, Cat#P1524 Sigma-Aldrich)
culture flasks at 37 °C in 5% CO2. Cell culture medium
was changed twice a week. Astrocytes were further puri-
fied by shaking at 200 rpm overnight at 33 °C, trypsinized,
and subcultured. After 3 days of stabilization, astrocytes
were incubated with the drugs in DMEM containing 6
mM L-glutamine and 50 μg/ml of streptomycin-50 U
penicillin. Cultures were routinely 95% astrocytes, as
assessed by glial fibrillary acidic protein (GFAP, Millipore
Cat#MAB360,RRID:AB_11212597) immunostaining. 3NP
was dissolved in phosphate-buffered saline (PBS) and pH
was adjusted to 7.4 with NaOH.
Immortalized striatal rat embryonic neurons which ex-
press a fragment of the N-terminal portion of normal hu-
man Htt (residues 1–548) with 15 glutamines or CAG
repeats ST14A/Q15 (Q15) (Cat#CH00066) or expressing
human mHtt with 120 glutamines or CAG repeats ST14A/
Q120 (Q120) (Cat#CH01137) were purchased from Coriell
Institute HD Community Biorepository. ST14A cells have
medium sized spiny neuron features [28, 29]. Cells were
grown in DMEM (Cat#12100-046) supplemented with 10%
heat inactivated fetal bovine serum (Cat#NTC-1000 Nato-
cor, Argentina), 2 mM L-glutamine (Cat#25030-081), and
100 μg/ml streptomycin-100 U penicillin (Cat#15140-122)
and kept at 33 °C in 5% CO2. Q15 and Q120 cells behave
very similarly in normal growth conditions until day 4
when Q120 cell number decreases, probably due to cell
death [31]. Thus, all experiments performed were run at 1
to 3 days after subcultivation.
Preparation of astrocyte-conditioned medium
Cortical and striatal astrocytes (8 × 104 cells) were plated
into 6-well plates and grown in DMEM containing 10%
fetal bovine serum for 72 h. To prepare each astrocyte-
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conditioned medium (ACM), each group of astrocytes
was incubated for 24 h in control conditions DMEM
without serum (ACM-CTRL) or plus BDNF 50 ng/ml
(ACM-BDNF), or with 3NP 15 mM (ACM-3NP) or 3NP
+ BDNF (ACM-3NP + BDNF). Then each ACM was
collected, centrifuged at 2000 rpm for 10 min to remove
cellular debris, and the supernatants stored at − 80 °C
until use. When necessary, just before incubating ACM
with ST14A neurons, we added 3NP 10 mM to the
ACM, or in some experiments we added ANA-12 (1
μM) and 3NP to the ACM.
Immunofluorescent identification of GFAP and ALDH1L1
in astrocytes
GFAP and aldehyde dehydrogenase 1 family member L1
(ALDH1L1) expression in astrocytes were evaluated by
indirect immunofluorescence. Astrocytes were fixed with
0.5 ml 4% paraformaldehyde in PBS for 30 min at 4 °C.
After rinsing with PBS, cells were incubated with 10%
normal goat serum in PBS with 0.1% Triton X-100 for
60 min. Then, slides were incubated overnight at 4 °C
with mouse anti-GFAP antibody (1:400, Millipore Cat#
MAB360, RRID:AB_11212597) or anti-ADLH1L1 (1:50,
Santa Cruz Biotechnology, Cat# sc-100497, RRID:AB_
2224180) in PBS with 0.1% Triton X-100 and 1% normal
goat serum. After rinsing, slides were incubated for 1 h
with goat anti-mouse Alexa 488 (1:800, Jackson Immu-
noResearch Labs Cat# 115-545-003, RRID:AB_2338840).
Slides were mounted with mounting medium containing
DAPI (Abcam) and visualized in a fluorescence micro-
scope Axiophot (Carl Zeiss, Germany). Negative control
slides were incubated with normal goat serum instead of
primary antibody. Acquisition was performed with a ×
40 objective. Fluorescence was determined using ImageJ
software and was normalized to the number of cells.
Cell viability assays
Trypan blue exclusion assay: Astrocytes or ST14A cells
(2 × 105 cells) were seeded onto 24-well plates and after
incubation cells were washed with PBS and trypsinized.
Pelleted cells were resuspended in DMEM + 10% fetal
bovine serum and 10 μl of cell suspension were stained
with 10 μl of Trypan blue. Viable cells that excluded
Trypan blue dye were counted in a Neubauer chamber,
and cell viability was expressed as number of live cells/
ml. Each condition was tested in triplicate in every
experiment.
MTT assay: Astrocytes (4 × 104 cells) were seeded
onto 96-well plates and after treatment cells were
washed with Krebs buffer and incubated for 3 h in 100
μl Krebs buffer plus 50 μg of MTT reagent dissolved in
10 μl of PBS at 37 °C. The developed crystals were dis-
solved in 100 μl 0.04 N HCl in isopropanol and optical
density was read in a microplate spectrophotometer al
595 nm.
Western blot analysis
Astrocytes (8–10 × 105 cells) and ST14A cells were lysed
and proteins obtained as previously described [32]. Pro-
tein concentration of samples was determined by the
Bradford assay. Then, 30–40 μg of proteins were size-
fractionated in an SDS-PAGE and electrotransferred to a
polyvinylidene difluoride membrane for 1 h at 4 °C or
overnight at room temperature for TrkB. Blots were
blocked for 1 h in 5% or 1% non-fat dry milk-TBS-0.1%
Tween 20 and incubated overnight with the appropriate
antibody. Anti-phosphorylated ERK (pERK, 1:200, Cell
Signaling Cat# 4376 RRID:AB_331772), GLT1 (1:1000,
Santa Cruz Biotechnology Cat# sc-365634,RRID:AB_
10844832), GLAST (1:1000 Santa Cruz Biotechnology
Cat# sc-515839), or TrkB (1:500 Millipore Cat# 07-
225RRID: AB_310445) antibodies were incubated in 5%
or 1% (for GLAST) non-fat dry milk in TBS-0.1% Tween
20. After washing, blots were incubated with the respect-
ive biotinylated HRP conjugated secondary antibody
(Abcam) for 1 h. Immunoreactivity was detected by en-
hanced chemiluminescence kit (Biolumina, PBL,
Argentina). After stripping, blots were incubated with
total ERK (1:1000 Santa Cruz Biotechnology Cat# sc-
135900, RRID:AB_2141283) or GAPDH (1:10000 Santa
Cruz Biotechnology Cat# sc-25778 RRID: AB_10167668)
antibodies, diluted in 5% non-fat dry milk-TBS-0.1%
Tween 20 at 4 °C. Blots were analyzed using SCION
Image software. Data were normalized to total ERK or
GAPDH and values expressed as increments relative to
the respective controls.
Cytokine release
Astrocytes (4 × 104 cells) were seeded onto 96-wellplates
and after 24-h incubation, culture media was immedi-
ately frozen at − 80°C until use. Tumour necrosis factor-
α (TNF-α) release was assessed by ELISA using a com-
mercial kit (BD Biosciences, Cat#555268 San Diego,
USA). Assays were performed following the manufac-
turer’s instructions. Cytokine values (pg/ml) were nor-
malized to the viability values obtained by the MTT
assay to account for variations in cell numbers caused by
the different treatments. For determination of transform-
ing growth factor-β (TGF-β) release, astrocytes (2 × 105
cells) were seeded onto 24-well plates and after 24-h in-
cubation, culture media was immediately frozen at − 80
°C until use. TGF-β release was assessed by ELISA using
a commercial kit (Cat#BMS249-4 Invitrogen Argentina).
Cytokine values (pg/ml) were normalized to the viability
values obtained by the Trypan blue exclusion assay to
account for variations in cell numbers caused by the dif-
ferent treatments.
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Statistical analysis
Data were expressed as mean ± SEM and analyzed by Stu-
dent’s t test, one-way or two-way ANOVA, followed by
Bonferroni multiple comparisons test using GraphPad
Prism 8 software. Normal distribution in every group was
tested using Anderson-Darling, D’Agostino-Pearson,
Shapiro-Wild, and Kolmogorov-Smirnov tests and equality
of variances was tested with Bartlett and Brown-Forsythe
tests (ANOVA assumptions). Differences with a p value <
0.05 were considered statistically significant. Experiments
were performed at least three times and the number of ex-
periments performed is specified in each figure legend.
Results
Characterization of region-specific astrocytes
We evaluated two specific markers of astrocytes: GFAP
and ALDH1L1 in rat astrocyte cultures derived from
cortical and striatal regions. Their expression was deter-
mined by immunocytochemistry. We found that GFAP
expression in cortical astrocytes was higher than in stri-
atal astrocytes (Fig. 1a, b). Regarding expression of
ALDH1L1, we found no changes between astrocytes
from the two areas studied (Fig. 1c, d).
BDNF protects cortical and striatal astrocytes from 3NP-
induced death.
We previously demonstrated that BDNF protects whole
brain-derived astrocytes against 3NP-induced death [18].
To investigate the effect of BDNF on 3NP-induced death
of cortical and striatal astrocytes, cells were treated with
or without 3NP (15 mM) and/or BDNF (50 ng/ml) and
viability was determined after 24 h. BDNF alone signifi-
cantly increased viability in cortical astrocytes (Fig. 2a).
3NP decreased the number of viable cells in cortical and
striatal astrocytes, but when co-incubated with BDNF,
astrocyte viability increased in both populations (Fig. 2a).
Next, we determined TrkB expression on cortical and stri-
atal astrocytes. As we showed previously, astrocytes in cul-
ture mainly express TrkB-T1 protein [18]. Therefore, we
measured TrkB-T1 protein expression by Western blot
analysis. In both astrocyte populations, BDNF increased
protein expression of TrkB-T1 regardless of 3NP presence
Fig. 1 Characterization of region-specific astrocytes. a GFAP expression in cortical and striatal astrocytes was assessed by immunocytochemistry
and normalized to the number of cells. Values represent the mean ± SEM of n = 3 independent experiments of GFAP fluorescence/cell
determined by ImageJ software. Differences between two groups were analyzed by Student’s t test (**p < 0.01 vs. striatal astrocytes). b
Representative merged images showing in green GFAP-positive cortical (left) and striatal (right) astrocytes and in blue their nuclei stained with
DAPI. c ALDH1L1 expression in cortical and striatal astrocytes was assessed by immunocytochemistry and normalized to the number of cells.
Values represent the mean ± SEM of n = 3 independent experiments of ALDH1L1 fluorescence/cell determined by ImageJ software. Differences
between two groups were analyzed by Student’s t test. d Representative merged images showing in green cortical (left) and striatal (right)
astrocytes positive for ALDH1L1 and in blue their nuclei stained with DAPI
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(Fig. 2b, c). 3NP significantly decreased protein levels of
this receptor only in cortical astrocytes (Fig. 2b). Also,
since we already proved that BDNF induces ERK activa-
tion in whole brain astrocytes [18], we verified if this is
also true for striatal and cortical astrocytes separately. We
confirmed that BDNF increased levels of pERK in cortical
and striatal astrocytes, and we found that, although show-
ing a tendency to decrease, 3NP did not significantly mod-
ify basal pERK activation in astrocytes (Fig. 2d, e). When
treated with 3NP + BDNF, activation of pERK was still
increased in both astrocyte populations (Fig. 2d, e). There-
fore, cortical and striatal astrocytes expressed functional
TrkB-T1 and BDNF protected both types of astrocytes
from 3NP toxicity.
BDNF increases protein expression of glutamate
transporters
To control glutamate in particular, astrocytes have spe-
cific transporters: GLT1 and GLAST. Since in HD the
expression of GLT1 decreases [22], we evaluated protein
Fig. 2 BDNF protects cortical and striatal astrocytes from 3NP-induced death. a Cell viability of cortical and striatal astrocytes treated for 24 h with
3NP 15 mM with or without BDNF 50 ng/ml was evaluated by Trypan blue exclusion assay. Values are the mean number of viable cells/ml ± SEM
of n = 4 independent experiments for cortical and striatal astrocytes. The effect of both factors BDNF and 3NP was analyzed by two-way ANOVA:
***p < 0.001 vs. control and ^p < 0.05 and ^^p < 0.01 vs. 3NP. Cortical (b) and striatal (c) astrocytes were incubated for 24 h with 3NP 15 mM
with or without BDNF 50 ng/ml and TrkB-T1 protein levels in total cell protein extracts were determined by Western blot. Values represent
arbitrary units of TrkB-T1/GAPDH ratio ± SEM of n = 4 independent experiments for cortical and striatal astrocytes. The effect of both factors
BDNF and 3NP was analyzed by two-way ANOVA: **p < 0.01 and ***p < 0.001 vs. control, ^^p < 0.01 and ^^^p < 0.001 vs. 3NP group. Cortical
(d) and striatal (e) astrocytes were incubated for 30 min with 3NP 15 mM and with or without BDNF 50 ng/ml and pERK/total ERK protein levels
in total cell protein extracts were determined by Western blot. Values represent arbitrary units of the pERK/total ERK ratio ± SEM of n = 5
independent experiments for cortical and striatal astrocytes. The effect of both factors BDNF and 3NP was analyzed by two-way ANOVA: ***p <
0.001 vs. control, ^^^p < 0.001 vs. 3NP group
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expression of these transporters in both astrocyte popu-
lations. We found that BDNF increased expression of
GLT1 in astrocytes from cortex and striatum, even in
the presence of 3NP (Fig. 3a, b). As for the GLAST
transporter, we found that BDNF increased GLAST ex-
pression only in cortical astrocytes (Fig. 3c), whereas in
striatal astrocytes, neither BDNF nor 3NP changed the
expression of the transporter (Fig. 3d).
BDNF modifies astrocyte cytokine release
One possible mechanism for BDNF protection in astro-
cytes could be reduction of the inflammatory response.
In order to evaluate the effect of BDNF on 3NP-induced
cytokine release, we determined levels of the pro-
inflammatory cytokine TNF-α and the anti-inflammatory
cytokine TGF-β in the astrocyte supernatant upon 3NP
treatment. TNF-α levels are increased in the striatum of
animals treated with 3NP [33]. Concordantly, 3NP-
induced release of TNF-α to the culture medium (Fig. 4a),
not detected in control or BDNF groups from both astro-
cyte populations. Surprisingly, astrocytes from the
striatum released 3 times higher levels of TNF-α than cor-
tical astrocytes, and BDNF decreased TNF-α release in-
duced by 3NP in both populations (Fig. 4a). To verify that
cortical astrocytes are indeed capable of releasing high
levels of TNF-α, we tested the effect of bacterial lipopoly-
saccharide (LPS), a potent pro-inflammatory stimulus, in
astrocytes [34]. LPS (1 μg/ml) induced a remarkable in-
crease of TNF-α levels secreted by cortical astrocytes and
the presence of BDNF did not change this effect (Fig. 4b).
However, striatal astrocytes release lower levels of TNF-α
in response to LPS than cortical astrocytes, similar to
3NP-induced levels (Fig. 4a, b). BDNF did not modify LPS
effect on TNF-α release in striatal astrocytes. Data suggest
that different inflammatory stimuli caused different astro-
cyte responses and that BDNF action is clearly specific to
inflammation induced by 3NP. TGF-β is a key mol-
ecule in brain development and brain homeostasis.
TGF-β is decreased in HD patients [35] and is known
to have an anti-inflammatory role in the brain [36].
Therefore, we investigated whether astrocytes from
cortex and striatum could release TGF-β in response
Fig. 3 BDNF increases protein expression of glutamate transporters. Cortical (a) and striatal (b) astrocytes were incubated for 24 h with 3NP 15
mM with or without BDNF 50 ng/ml and GLT1 protein levels in total cell protein extracts were determined by Western blot. Values represent
arbitrary units of the GLT1/GAPDH ratio ± SEM of n = 5 independent experiments for cortical and 4 independent experiments for striatal
astrocytes. The effect of both factors BDNF and 3NP was analyzed by two-way ANOVA *p < 0.05 and ***p < 0.001 vs. control group ^p < 0.05
and ^^^p < 0.001 vs. 3NP group. Cortical (c) and striatal (d) astrocytes were incubated for 24 h with 3NP 15 mM with or without BDNF 50 ng/ml
and GLAST protein levels in total cell proteins extracts were determined by Western blot. The values represent arbitrary units of the GLAST/
GAPDH ratio ± SEM of n = 4 independent experiments for cortical and n = 5 independent experiments for striatal astrocytes. The effect of both
factors BDNF and 3NP was analyzed by two-way ANOVA. ***p < 0.001 vs. control group
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to 3NP or BDNF. We found that 3NP, alone or in
the presence of BDNF, decreased TGF-β release,
whereas BDNF per se did not modify the release of
TGF-β from cortical astrocytes (Fig. 4c). In striatal as-
trocytes, 3NP had no effect on TGF-β release and
BDNF increased TGF-β release of striatal astrocytes
regardless of the presence of 3NP (Fig. 4d). Consid-
ered altogether, our data indicate that cortical and
striatal astrocytes responded differently to 3NP action.
Striatal astrocytes released more TNF-α and cortical
astrocytes less TGF-β in response to 3NP. Neverthe-
less, BDNF exerted an anti-inflammatory effect on
both populations.
BDNF protects ST14A/Q120 neurons from 3NP-induced
cell death.
Given that BDNF is required for striatal neuron survival
[37], we determined BDNF effect on striatal neurons.
For this purpose, we used rat striatal embryonic neur-
onal cell line ST14A expressing normal human Htt with
15 CAG repeats (Q15) and ST14A cells expressing hu-
man mHtt with 120 CAG repeats (Q120) [31], as a
cellular model of HD. First, we confirmed that both cell
lines expressed TrkB-FL (Fig. 5a). Then we tested
whether BDNF could protect Q15 and Q120 cells from
3NP-induced death. BDNF per se did not modify Q15 or
Q120 cell viability, but BDNF partially blocked 3NP-
induced cell death in Q120 neurons (Fig. 5c). Surpris-
ingly, BDNF did not inhibit death of Q15 cells induced
by 3NP (Fig. 5b). These results suggest that BDNF se-
lectively protected neurons expressing mHtt.
Differential effect of astrocyte-conditioned medium from
BDNF treated astrocytes on neuron viability
Our previous results showed that conditioned media
from BDNF-treated astrocytes protects PC12 cells from
death induced by 3NP [18]. Since BNDF increases astro-
cyte viability and function, we wondered if BDNF-
treated astrocytes could have a protective effect in a cel-
lular model of HD. Therefore, we evaluated whether
astrocyte-conditioned media (ACM) could induce neu-
roprotection in Q15 and Q120 striatal neurons. First, we
treated whole brain astrocytes without (ACM-CTRL) or
with BDNF (ACM-BDNF) for 24 h and then Q15 and
Fig. 4 BDNF modifies astrocyte cytokine release. Cortical and striatal astrocytes were treated for 24 h with 3NP 15 mM with or without BDNF 50
ng/ml (a) or with LPS 1 μg/ml with or without BDNF 50 ng/ml (b). TNF-α release into the culture supernatant was assessed by ELISA and
normalized to viability values obtained with the MTT assay for each experimental group. Data are the mean ± SEM of n = 3 independent
experiments. Differences between two groups were analyzed by Student’s t test. ^p < 0.05 vs. 3NP group. Cortical (c) and striatal (d) astrocytes
were treated for 24 h with 3NP 15 mM with or without BDNF 50 ng/ml. TGF-β release into the culture supernatant was assessed by ELISA and
normalized to viability values obtained by Trypan blue exclusion assay for each experimental group. Data are the mean ± SEM of n = 3
independent experiments. The effect of both factors BDNF and 3NP was analyzed by two-way ANOVA. *p < 0.05 vs. control group ^p < 0.05 vs.
3NP group
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Q120 cells were incubated with ACM from whole brain
astrocytes in the presence or absence of 3NP for 24 h
(Fig. 6a). In this set of experiments, we discovered that
ACM-CTRL and ACM-BDNF did not modify viability of
Q15 cells in any condition tested (Fig. 6b). Conversely,
although ACM per se had no effect on Q120 cell viabil-
ity, only ACM-BDNF partially protected Q120 neurons
from 3NP-induced death (Fig. 6c). Data indicate that the
effect of ACM-BDNF was selective to cells expressing
mHtt. To further examine the neuroprotective effect of
ACM-BDNF, we treated cortical and striatal astrocytes
without (ACM-CTRL) or with BDNF (ACM-BDNF) for
24 h and used these ACM to incubate Q120 cells, in the
presence or absence of 3NP, for 24 h (Fig. 6d). Also, we
added ANA-12, an antagonist of the TrkB receptor, to
the ACM-BDNF in order to block the action exerted by
any remnant of BDNF in the ACM (Fig. 6d). We found
that ACM-CTRL and ACM-BDNF from cortical astro-
cytes either with or without addition of ANA-12 did not
protect Q120 cells from 3NP-induced cell death (Fig.
6e). ACM-CTRL from striatal astrocytes did not modify
Q120 cell viability but ACM-BDNF from striatal astro-
cytes increased Q120 viability in the presence of 3NP
(Fig. 6f). Since addition of ANA-12 in ACM-BDNF did
not modify the effect of ACM-BDNF on Q120 neuron
viability, we confirmed that the effect observed was ex-
clusively due to ACM-BDNF action and not to any
remnant of BDNF in the ACM. These results strengthen
the idea that only striatal astrocytes treated with BDNF
released neuroprotective factors able to prevent 3NP
toxicity in neurons expressing mHtt. We also tested the
effect of ACM from cortical or striatal astrocytes treated
for 24 h with 3NP (ACM-3NP) or with 3NP and BDNF
(ACM-3NP + BDNF) on Q15 and Q120 cell survival
(Fig. 7a). None of the ACM from cortical astrocytes al-
tered viability of Q15 cells (Fig. 7b). Remarkably, ACM-
3NP and ACM-3NP + BDNF from striatal astrocytes di-
minished Q15 cell viability in a similar way (Fig. 7c), in-
dicating that ACM-3NP from striatal astrocytes,
regardless of the presence of BDNF, was more toxic than
cortical ACM-3NP. Concerning Q120 cells, we found
that cortical ACM-3NP and cortical ACM-3NP + BDNF
induced their death (Fig. 7d), confirming that Q120 cells
are more sensitive to toxic stimuli than Q15 cells. ACM-
3NP from striatal astrocytes seemed slightly more effect-
ive than cortical ACM-3NP in inducing Q120 cell death
(Fig. 7e). Nevertheless, ACM-3NP + BDNF had a less
toxic effect since ACM-3NP + BDNF increased Q120
neuron viability compared to ACM-3NP (Fig. 7e). These
results reinforce that only striatal astrocytes treated with
BDNF release neuroprotective factors able to protect
mHtt expressing neurons from 3NP toxicity.
Discussion
Astrocytes have traditionally been viewed as simple
homogenous cells providing support to neurons. We
now recognize that astrocytes from different brain re-
gions are heterogeneous [38]. Here, we characterized as-
trocytes form cortex and striatum, two areas involved in
HD pathogenesis. Cortical astrocytes in culture express
higher levels of GFAP than striatal astrocytes. Similar re-
sults for in vivo experiments assaying GFAP expression
Fig. 5 BDNF protects ST14A/Q120 neurons from 3NP-induced cell death. a TrkB-FL and β3-tubulin protein levels in total cell protein extracts of
Q15 or Q120 cells in control conditions were determined by Western blot. Image shows one representative blot out of two. Q15 (b) and Q120 (c)
cells were incubated with 3NP 10 mM with or without BDNF 100 ng/ml for 24 h and cell viability was evaluated by Trypan blue exclusion assay.
Values are the mean ± SEM of viable cells/ml of n = 3 independent experiments. The effect of both factors BDNF and 3NP was analyzed by two-
way ANOVA. *p < 0.05, ***p < 0.001 vs. control group and ^p < 0.05 vs. 3NP group
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Fig. 6 Regional difference in ACM from BDNF-treated astrocytes effect on neuron viability. a Time schedule of ACM collection and treatment. ACM was
prepared from astrocytes treated for 24 h with BDNF 50 ng/ml (ACM-BDNF) or without (ACM-CTRL). Q15 and Q120 cells were treated for 24 h with 3NP
(10 mM) added to each ACM. Effects of ACM on viability of Q15 (b) or Q120 (c) cells were evaluated by Trypan blue exclusion assay. Data represent the
mean number of viable cells/ml ± SEM of n = 4 experiments. Differences between all groups were analyzed by One-way ANOVA followed by Bonferroni’s
multiple comparison post-test. ***p < 0.001 vs. DMEM and ^^p < 0.01 vs. ACM-CTRL + 3NP. d Time schedule of ACM collection and treatment. ACM was
prepared from astrocytes treated for 24 h with BDNF 50 ng/ml (ACM-BDNF) or without (ACM-CTRL). Q15 and Q120 cells were treated for 24 h with 3NP
(10 mM) and if necessary, ANA-12 (1 μM) was added to ACM. Q120 cells were treated with ACM from cortical (e) or striatal (f) astrocytes. Values represent
the mean number of viable cells ml ± SEM of n = 4 experiments. Differences between all groups were analyzed by one-way ANOVA followed by
Bonferroni’s multiple comparison post-test. **p < 0.01, ***p < 0.001 vs. control and ^^p < 0.01 vs. ACM-CTRL + 3NP
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by proteomic and transcriptomic analysis showed that
striatal astrocytes had lower levels of GFAP expression
than hippocampal astrocytes [39]. Chai and collaborators
also demonstrated that cortical astrocytes and hippo-
campal astrocytes were really similar when comparing
RNA sequencing data but hippocampal and striatal
astrocytes were shown to be different populations. Given
that culture astrocytes are mechanically manipulated,
they are likely to be reactive. However, as we showed in
this work, control astrocytes did not secrete detectable
levels of TNF-α, and they preserve the ability to be acti-
vated by 3NP or LPS, showing that they can react
Fig. 7 Regional difference in ACM from 3NP+BDNF-treated astrocytes on neuron viability. a Time schedule of ACM collection and treatment.
Cortical or striatal astrocytes were treated for 24 h with DMEM (ACM-CTRL), or 3NP 15 mM (ACM-3NP), or 3NP 15 mM and BDNF 50 ng/ml (ACM-
3NP + BDNF). Q15 and Q120 cells were treated for 24 h with those ACM. Q15 cells were incubated for 24 h in the presence or absence of ACM
from cortical (b) and striatal (c) astrocytes. Q120 cells were incubated for 24 h in the presence or absence of ACM from cortical (d) and striatal (e)
astrocytes. Cell viability was evaluated by Trypan blue exclusion assay. Data show mean number of viable cells/ml ± SEM of n = 4 experiments.
Differences between all groups were analyzed by one-way ANOVA followed by Bonferroni´s multiple comparison post-test. **p < 0.01, ***p <
0.001 vs. control and ^p < 0.05 vs. ACM-3NP
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similarly to in vivo astrocytes. Our results indicate that
cortical and striatal astrocytes in culture mirrored some
differences and features of in vivo astrocytes.
Although numerous studies focus on BDNF effects on
neuron development and survival, surprisingly little is
known about BDNF effects on astrocytes. We already
demonstrated that BDNF prevents apoptotic death of
whole brain rat astrocytes induced by serum deprivation
and 3NP stimuli [18]. 3NP is a toxin resembling HD
mitochondrial dysfunction. It is widely used as an
in vitro model of HD, causing striatal degeneration as it
occurs in HD [27]. Moreover, 3NP toxicity induces the
decrease of GFAP immunoreactivity by affecting the re-
moval of glutamate from the synaptic cleft, cell survival,
and reducing the release of trophic factors [40]. Here,
we demonstrate that BDNF protects cortical and striatal
astrocytes from 3NP-induced death, mainly through
TrkB-T1. Although in striatal astrocytes protein levels of
TrkB-T1 seem to be higher, both astrocyte populations
can respond to BDNF. Also, BDNF increased its own re-
ceptor TrkB-T1 expression and signaling by activating
ERK. We previously demonstrated ERK activation in
whole brain astrocytes [18]. Thus, BDNF activates TrkB-
T1 and ERK signaling, resulting in increased survival of
both cortical and striatal astrocytes. This finding agrees
with other studies where TrkB-T1 function participates
in morphogenesis of cortical astrocytes [19] and where
TrkB-T1 KO astrocytes demonstrated downregulation of
migration and proliferation pathways [41].
Impairment of glutamate signaling or uptake is associ-
ated with many neurological disorders, including HD.
Alteration of glutamate receptor distribution and signal-
ing at cortico-striatal synapses and alteration of glutam-
ate release contribute to onset of the disease [42]. Our
results indicate that 3NP did not modify the expression
of GLT1 or GLAST transporter, whereas BDNF mark-
edly increased GLT1 expression in both cortical and stri-
atal astrocytes. BDNF regulated GLAST expression
differently since it was increased only in cortical astro-
cytes. Strong evidence shows progressive loss of GLT1
expression in HD mouse models [42]. Given that GLT1
has a predominant role in glutamate uptake, BDNF
could diminish GLT1 loss in HD, thereby contributing
to its beneficial effects in HD models. We have proved
before that BDNF increases intracellular levels of gluta-
thione, the main antioxidant molecule, which is formed
by glutamate, and removes excess of reactive oxygen
species [18]. We consider that increasing GLT1 contrib-
uted directly to maintenance of the cortical-striatal regu-
lation of glutamate uptake and can also contribute to
glutathione generation and avoidance of neuron dys-
function. Further in vivo studies are needed in order to
reinforce astrocytes as therapeutic targets for ameliorat-
ing HD neuropathology.
Pro-inflammatory cytokines were reported to regulate
glutamate transporters both in vivo and in vitro [43].
TNF-α, a well-known inhibitor of glutamate re-uptake,
could also induce oxidative stress and neuron death [44].
TNF-α protein levels in the striatum are increased in an
HD model induced by 3NP [33] and in a transgenic HD
mouse model R6/2 [45]. Moreover, when post-mortem
HD striatal tissue was evaluated, TNF-α striatal mRNA
was higher in HD patients [46] and thus excessive TNF-
α was proposed to be one mechanism of neurodegenera-
tion [47]. Here, we found that 3NP stimulates release of
TNF-α in both astrocyte populations, but striatal astro-
cytes have a greater response to 3NP than cortical astro-
cytes. Striatal astrocytes were even shown to have the
highest levels of peroxide production and necrotic cell
death rates compared to cortical and mesencephalic
astroglia in response to 3NP [48], reinforcing the idea
that striatal astrocytes are more susceptible to mitochon-
drial dysfunction by 3NP. More interestingly, BDNF de-
creased TNF-α release induced by 3NP, indicating that
BDNF may have an underappreciated anti-inflammatory
role in the brain. Regarding LPS, a strong pro-
inflammatory stimulus, we found that astrocytes react
oppositely compared to their reaction to 3NP. In this ex-
periment, cortical astrocytes released greater amounts of
TNF-α than striatal astrocytes, and BDNF had no effect
on LPS action. Thus, BDNF action is specific to 3NP-
induced inflammation. Data suggest that astrocyte het-
erogeneity must be considered in order to evaluate their
anti-inflammatory response. TGF-β can be essential for
many processes such as neurogenesis, synapse forma-
tion, gliogenesis, and angiogenesis [49]. Recently, inter-
esting data show that TGF-β deficiency could affect loss
of astrocyte glutamate transporters such as GLT1 or
GLAST, and also decreased glutamate uptake [50]. Con-
cordantly, TGF-β expression is decreased in HD patients
[35]. In the present work, we found that astrocytes re-
spond differently to 3NP insult. Although 3NP decreased
the levels of TGF-β in cortical astrocytes, it did not
modify TGF-β release in striatal astrocytes. In contrast,
whereas BDNF per se did not modify TGF-β levels in
cortical astrocytes, it increased TGF-β release selectively
from striatal astrocytes. These results suggest that cor-
tical astrocytes decreased TGF-β release in response to
3NP possibly affecting astrocyte inflammatory response.
Striatal astrocytes can respond to BDNF by increasing
TGF-β. Restoring TGF-β in striatal astrocytes could be
beneficial in the context of neurodegenerative processes
such as HD.
BDNF is a widely known protective neurotrophic fac-
tor: in in vivo models, transport of BDNF is markedly
decreased in cortical neurons and over expression of
BDNF rescues changes in neuron structures and func-
tion in HD mice model [51]. BDNF suppresses
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autophagy induced by 3NP [52], and prevents death by
3NP in rat cortical neurons [53]. In our work, 3NP ef-
fectively induced neuron death and BDNF protected
Q120 cells expressing mHtt. Unexpectedly, BDNF did
not prevent 3NP-induced death in Q15 cells. Similar re-
sults were reported by Martire et al. [54], where BDNF
prevented NMDA toxicity selectively in Q120 but not in
Q15 cells. Since both Q15 and Q120 neurons express
TrkB-FL, BDNF failure to protect Q15 might involve de-
fective TrkB signaling. It is also possible that this cell
line is less susceptible to external stimuli than primary
neurons, and that expression of mHtt, but not Htt,
markedly increases susceptibility to damage.
Aside from astrocyte dysfunction, gain of function in
astrocytes was also shown to contribute to the toxicity
observed in neurodegenerative diseases [55]. A recent
study on HD astrocyte transcriptome and proteome sug-
gests that in HD models, striatal astrocytes lose their
functions rather than acquire a toxic phenotype [26], al-
though further studies are needed to univocally prove
this hypothesis. On the other hand, many studies have
provided strong evidence that astrocytes actively contrib-
ute to neuroprotection [56]. In fact, glial-conditioned
medium is rich in antioxidants and neurotrophic factors
that may help protect damaged neurons [57]. We previ-
ously demonstrated that ACM from BDNF-treated as-
trocytes protected PC12 neurons from 3NP toxicity [18].
Now, we show that ACM from BDNF-treated astrocytes
exerted selective protection of mHtt expressing striatal
neurons without affecting normal Htt expressing cells.
Moreover, when differentiating cortical from striatal
ACM, protection was exerted only by ACM from
BDNF-treated striatal astrocytes. This was not due to
remaining BDNF in the culture media because blocking
it by adding ANA-12 to the ACM did not modify the ef-
fect of ACM-BDNF on Q120 cell viability. Concerning
cortical ACM-3NP and striatal ACM-3NP, both induced
Q120 cell death which could be due to TNF-α released
by astrocytes in response to 3NP. Actually, excesses of
TNF-α coactivate astrocytes resulting in neuron dysfunc-
tion and ultimately neuron death [58]. Only striatal
ACM from 3NP + BDNF-treated astrocytes increased
Q120 cell viability. Therefore, striatal ACM-BDNF, un-
like cortical ACM-BDNF, contains soluble factors that
exert neuroprotection. TGF-β might be one protective
factor released by astrocytes upon BDNF stimulation, al-
though further studies measuring other soluble factors
such as growth factors, cytokines, and neuropeptides are
needed to fully elucidate these mechanisms.
A number of studies suggest that heterogeneity of as-
trocytes must be considered in regard to neurodegenera-
tive progression [59]. One study in particular recently
evidenced the difference between striatal astrocytes and
mesencephalic astrocytes [60]. Asanuma et al. (2019)
demonstrated that striatal astrocytes promoted stronger
neuroprotection than mesencephalic astrocytes against
oxidative stress. They attributed this difference to the al-
tered expression of genes induced in these brain areas
and showed that striatal astrocytes upregulate antioxi-
dant and detoxifying pathways compared to midbrain
astrocytes.
Few studies have investigated the differences between
astrocytes from different regions. Given the complexity
of the CNS, only in the last decades have studies on glial
responses in vivo began to be conducted. Primary cul-
tured astrocytes have proved to be an important tool in
elucidating glial physiology since 1980 [61]. Neverthe-
less, cultured astrocytes are not equal to in vivo astro-
cytes since for example they modify gene expression in
the presence of fetal serum added to primary cultures
[62]. This study shows that isolation of astrocytes by
immunopanning technique yields astrocytes with a more
similar pattern of gene expression to that of in vivo as-
trocytes than do traditional primary astrocyte cultures.
However, ACM from classical astrocyte cultures exhibit
the same protective effect on neuron survival than ACM
from astrocytes isolated by immunopanning technique.
Moreover, astrocytes isolated by immunopanning tech-
nique also increase synapse formation and function in a
similar way as classically cultured astrocytes do. Thus,
astrocytes change under culture conditions but they still
perform functions that can help understand glial biology.
We present here clear differences between cortical and
striatal astrocytes. Although in vivo studies are needed
to confirm this data, our results strongly suggest that
striatal astrocytes, though more susceptible to HD-like
toxic stimulus, exert neuroprotection in mHtt expressing
neurons in response to BDNF.
Conclusions
All the findings presented here point to a critical role for
BDNF-treated striatal astrocytes in preventing striatal
dysfunction and also in providing neuronal support in
an HD-like context. Importantly, our results demon-
strate that cortical and striatal astrocytes differed in their
response to toxic and protective stimuli, thereby further
proving their heterogeneity. Understanding astrocyte
heterogeneity is paramount for unraveling their protect-
ive potential in neurodegenerative disorders.
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